Computational approaches for drug repurposing in oncology: untapped opportunity for high value innovation

Shraddha M Dalwadi; Andrew Hunt; Mark D Bonnen; Yohannes T Ghebre

doi:10.3389/fonc.2023.1198284

Computational approaches for drug repurposing in oncology: untapped opportunity for high value innovation

Front Oncol. 2023 May 18:13:1198284. doi: 10.3389/fonc.2023.1198284. eCollection 2023.

Authors

Shraddha M Dalwadi¹, Andrew Hunt¹, Mark D Bonnen¹, Yohannes T Ghebre¹

Affiliation

¹ Department of Radiation Oncology, The University of Texas Health Science Center at San Antonio, San Antonio, TX, United States.

Abstract

Historically, the effort by academia and industry to develop new chemical entities into lifesaving drugs has limited success in meeting the demands of today's healthcare. Repurposing drugs that are originally approved by the United States Food and Drug Administration or by regulatory authorities around the globe is an attractive strategy to rapidly develop much-needed therapeutics for oncologic indications that extend from treating cancer to managing treatment-related complications. This review discusses computational approaches to harness existing drugs for new therapeutic use in oncology.

Keywords: clinical trials; drug repurposing; informatics; oncology; pharmacology.

Publication types

Review

Grants and funding

The study was supported in part by NIH grant P30 CA125123 which supports the Dan L. Duncan Comprehensive Cancer Center (DLDCCC) at Baylor College of Medicine (BCM). YG is supported by grants from the NHLBI (grant numbers K01HL118683; R01HL137703), NIAMS (grant numbers R56AR077445; R01AR077445), American Heart Association (grant number 17GRNT33460159), the Cancer Prevention and Research Institute of Texas (grant number RP190497), and by intramural funding from BCM and The University of Texas Health Science Center at San Antonio (UT Health San Antonio). This content is solely the responsibility of the authors and does not necessarily represent the official views of the sponsors.